Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.54 Million EUR | -48.75% |
| 2022 | 37.99 Million EUR | 99.03% |
| 2021 | 19.08 Million EUR | -38.01% |
| 2020 | 30.79 Million EUR | 1.25% |
| 2019 | 30.41 Million EUR | 22.97% |
| 2018 | 24.73 Million EUR | 6.86% |
| 2017 | 23.14 Million EUR | 7.33% |
| 2016 | 21.56 Million EUR | 33.57% |
| 2015 | 16.14 Million EUR | 10.73% |
| 2014 | 14.57 Million EUR | 3.12% |
| 2013 | 14.13 Million EUR | -7.64% |
| 2012 | 15.3 Million EUR | -20.92% |
| 2011 | 19.35 Million EUR | -33.49% |
| 2010 | 29.1 Million EUR | 5.37% |
| 2009 | 27.62 Million EUR | 245.23% |
| 2008 | -19.02 Million EUR | -6.51% |
| 2007 | -17.85 Million EUR | -36.42% |
| 2006 | -13.09 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.17 Million EUR | -3.62% |
| 2024 Q2 | 5.22 Million EUR | 0.97% |
| 2023 Q3 | 5.36 Million EUR | 2.72% |
| 2023 FY | 19.47 Million EUR | -48.75% |
| 2023 Q4 | 5.36 Million EUR | 0.0% |
| 2023 Q1 | 4.92 Million EUR | -65.06% |
| 2023 Q2 | 5.22 Million EUR | 6.12% |
| 2022 Q4 | 14.08 Million EUR | 0.0% |
| 2022 Q1 | 4.92 Million EUR | -37.63% |
| 2022 Q2 | 3.43 Million EUR | -30.21% |
| 2022 Q3 | 14.08 Million EUR | 309.68% |
| 2022 FY | 37.99 Million EUR | 99.03% |
| 2021 FY | 19.08 Million EUR | -38.01% |
| 2021 Q3 | 4.95 Million EUR | 14.86% |
| 2021 Q2 | 4.31 Million EUR | -5.67% |
| 2021 Q4 | 7.9 Million EUR | 59.42% |
| 2021 Q1 | 4.57 Million EUR | -63.22% |
| 2020 Q4 | 12.43 Million EUR | 32.02% |
| 2020 FY | 30.79 Million EUR | 1.25% |
| 2020 Q2 | 8.28 Million EUR | 3.93% |
| 2020 Q3 | 9.41 Million EUR | 13.73% |
| 2020 Q1 | 7.96 Million EUR | -1.91% |
| 2019 Q2 | 7.68 Million EUR | 4.89% |
| 2019 Q4 | 8.12 Million EUR | 11.55% |
| 2019 FY | 30.41 Million EUR | 22.97% |
| 2019 Q1 | 7.32 Million EUR | 32.05% |
| 2019 Q3 | 7.28 Million EUR | -5.17% |
| 2018 FY | 24.73 Million EUR | 6.86% |
| 2018 Q1 | 5.95 Million EUR | 2.78% |
| 2018 Q4 | 5.54 Million EUR | -22.04% |
| 2018 Q3 | 7.11 Million EUR | 16.26% |
| 2018 Q2 | 6.11 Million EUR | 2.79% |
| 2017 Q4 | 5.79 Million EUR | 3.8% |
| 2017 Q3 | 5.57 Million EUR | -11.56% |
| 2017 Q2 | 6.3 Million EUR | 15.4% |
| 2017 Q1 | 5.46 Million EUR | -7.87% |
| 2017 FY | 23.14 Million EUR | 7.33% |
| 2016 Q1 | 4.7 Million EUR | 6.66% |
| 2016 FY | 21.56 Million EUR | 33.57% |
| 2016 Q2 | 4.38 Million EUR | -6.84% |
| 2016 Q4 | 5.93 Million EUR | -9.27% |
| 2016 Q3 | 6.53 Million EUR | 49.12% |
| 2015 FY | 16.14 Million EUR | 10.73% |
| 2015 Q4 | 4.41 Million EUR | 6.65% |
| 2015 Q3 | 4.13 Million EUR | 5.51% |
| 2015 Q2 | 3.92 Million EUR | 6.81% |
| 2015 Q1 | 3.67 Million EUR | 3.49% |
| 2014 Q4 | 3.54 Million EUR | -4.55% |
| 2014 FY | 14.57 Million EUR | 3.12% |
| 2014 Q3 | 3.71 Million EUR | 5.99% |
| 2014 Q2 | 3.5 Million EUR | -7.86% |
| 2014 Q1 | 3.8 Million EUR | 11.84% |
| 2013 Q4 | 3.4 Million EUR | -7.63% |
| 2013 FY | 14.13 Million EUR | -7.64% |
| 2013 Q1 | 3.57 Million EUR | -18.98% |
| 2013 Q2 | 3.47 Million EUR | -2.74% |
| 2013 Q3 | 3.68 Million EUR | 5.98% |
| 2012 Q2 | 3.89 Million EUR | 8.03% |
| 2012 Q4 | 4.41 Million EUR | 29.54% |
| 2012 FY | 15.3 Million EUR | -20.92% |
| 2012 Q3 | 3.4 Million EUR | -12.47% |
| 2012 Q1 | 3.6 Million EUR | -64.61% |
| 2011 Q1 | 3.67 Million EUR | -66.29% |
| 2011 Q2 | 3.46 Million EUR | -5.66% |
| 2011 Q3 | 3.01 Million EUR | -12.96% |
| 2011 Q4 | 10.17 Million EUR | 237.4% |
| 2011 FY | 19.35 Million EUR | -33.49% |
| 2010 Q4 | 10.89 Million EUR | 80.74% |
| 2010 Q2 | 6.03 Million EUR | -1.79% |
| 2010 Q3 | 6.02 Million EUR | -0.13% |
| 2010 Q1 | 6.14 Million EUR | -14.48% |
| 2010 FY | 29.1 Million EUR | 5.37% |
| 2009 Q2 | 6.59 Million EUR | 8.71% |
| 2009 Q4 | 7.18 Million EUR | -7.62% |
| 2009 Q3 | 7.78 Million EUR | 18.02% |
| 2009 FY | 27.62 Million EUR | 245.23% |
| 2009 Q1 | 6.06 Million EUR | 0.0% |
| 2008 FY | -19.02 Million EUR | -6.51% |
| 2007 FY | -17.85 Million EUR | -36.42% |
| 2006 FY | -13.09 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioNTech SE | 2.52 Billion EUR | 99.188% |
| CureVac N.V. | 211.75 Million EUR | 90.3% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 84.985% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 84.985% |
| BRAIN Biotech AG | 24.94 Million EUR | 17.646% |
| Formycon AG | 23.73 Million EUR | 13.454% |
| Heidelberg Pharma AG | 27.81 Million EUR | 26.157% |